INTRODUCTION AND OBJECTIVES: In recent years, medical expulsive therapy has been questioned in the management of distal ureteric stones. Therefore, we conducted a prospective randomized study to evaluate the possible role of tadalafil individually and in comparison with proven tamsulosin as well as a placebo therapy in distal ureteric stone expulsion.
METHODS: Between January 2015 and March 2016, 327 patients who presented with distal ureteric stones of size 5e10 mm were randomly divided into three groups: tadalafil (Group A), tamsulosin (Group B), and placebo (Group C). Therapy was given for a maximum of 4 weeks. Stone expulsion rate, time to stone expulsion, analgesic use, number of hospital visits for pain, follow-up, endoscopic treatment and adverse effects of drugs were noted.
RESULTS: A statistically significant expulsion rate of 86.0% in Group A compared with 66.0% in Group B and 38.0% in Group C was observed. Also a shorter stone expulsion time in Group A (13.5 AE 2.5) in comparison to Group B (16.4 AE 3.5) and Group C (24.8 AE 4.5) was observed. Statistically significant differences were noted in renal colic episodes and analgesic requirement in Group A in comparison to Group B and Group C. No serious adverse effects were noted.
CONCLUSIONS: Tadalafil is safe, efficacious, and well tolerated as medical expulsive therapy for distal ureteric stones. This study showed that tadalafil increases ureteric stone expulsion quite significantly along with better control of pain and significantly lower analgesic requirement. METHODS: Prospective, randomized, simple-blind, shamcontrolled study. 58 patients with vasculogenic ED refractory to PDE5i were randomized into two groups. 30 were treated with electrohydraulic LIST (1 session/week for 6 weeks; 1,500 pulses of 0.10 mJ/mm2 at 5 Hz) and 28 were treated with a sham probe. 11 patients withdrew from the study and were lost to follow-up. Patients were evaluated at baseline and 1 month after the end of treatment using validated ED questionnaires. Fisher's exact or Student's t-test were used. Results were considered statistically significant at p<0.05 RESULTS: 27 active-treated patients and 20 sham-treated patients completed the one-month follow-up. There was no significant difference between the two groups in baseline characteristics. Baseline five-item version of the International Index of Erectile Function (IIEF-5) mean scores, in the active and sham groups, were 10.0 AE 3.9 and 10.0 AE 4.5, respectively (p¼ 0.863). At baseline, 48.1% of patients in the active group and 50.0% of patients in the placebo group had a positive answer to the Sexual Encounter Profile (SEP) 2 question (p¼1.000); 11.1% of patients in the active group and 10.0% of patients in the placebo group had a positive answer to the SEP 3 question (p¼1.000). One month after treatment IIEF-5 scores mean changes from baseline, in the active and placebo group, were 1.6 AE 4.7 and 0.5 METHODS: Systematic search of MEDLINE, EMBASE, and ClinicalTrials.gov for randomized controlled trials that had been published in peer-reviewed journals or presented in abstract form of Li-ESWT used for the treatment of erectile dysfunction between January 2010 and March 2016. Randomized controlled trials were eligible for inclusion if they were published in the peer-reviewed literature and assessed erectile function outcomes using the IIEF-EF. Estimates were pooled using random-effects meta-analysis. The main outcome measure was the change in IIEF-EF after treatment with Li-ESWT in patients treated with active treatment and sham LiESWT probes.
Source of Funding: None
RESULTS: Data were extracted from 7 trials involving 602 participants. The average age was 60.7 years and the average followup was 19.8 weeks. There was a statistically significant improvement in pooled change in IIEF-EF from baseline to follow-up in men undergoing Li-ESWT compared to those undergoing sham therapy (6.40 points [95% CI: 1.78 to 11.02; I2 ¼ 98.7%, P < 0.0001] vs. 1.65 points [95% CI: 0.92 to 2.39; I2 ¼ 64.6%, P < 0.0001]; between-group difference, P ¼ 0.047). Significant between-group differences were found for total treatment shocks received by patients (P < 0.0001).
CONCLUSIONS: In this meta-analysis of seven randomized controlled trials, treatment of ED with Li-ESWT resulted in a significant increase in IIEF-EF scores.
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